nodes	percent_of_prediction	percent_of_DWPC	metapath
Raltegravir—CCR1—Chemokine receptors bind chemokines—CXCL8—melanoma	0.00322	0.00673	CbGpPWpGaD
Raltegravir—CCR1—GPCRs, Class A Rhodopsin-like—CXCR2—melanoma	0.00313	0.00654	CbGpPWpGaD
Raltegravir—CCR1—GPCR ligand binding—F2RL1—melanoma	0.00302	0.00632	CbGpPWpGaD
Raltegravir—CCR1—Peptide ligand-binding receptors—CXCR4—melanoma	0.00292	0.00611	CbGpPWpGaD
Raltegravir—CCR1—GPCR ligand binding—GRM3—melanoma	0.00284	0.00594	CbGpPWpGaD
Raltegravir—UGT1A1—Irinotecan Pathway—APC—melanoma	0.00276	0.00577	CbGpPWpGaD
Raltegravir—CCR1—GPCR ligand binding—KISS1—melanoma	0.0027	0.00563	CbGpPWpGaD
Raltegravir—CCR1—Class A/1 (Rhodopsin-like receptors)—CXCR2—melanoma	0.00268	0.00561	CbGpPWpGaD
Raltegravir—CCR1—GPCRs, Class A Rhodopsin-like—F2R—melanoma	0.00266	0.00556	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—TAS2R60—melanoma	0.00265	0.00554	CbGpPWpGaD
Raltegravir—CCR1—GPCR ligand binding—CXCR1—melanoma	0.00261	0.00545	CbGpPWpGaD
Raltegravir—CCR1—GPCRs, Class A Rhodopsin-like—EDNRB—melanoma	0.00258	0.00539	CbGpPWpGaD
Raltegravir—CCR1—GPCR ligand binding—MC1R—melanoma	0.00257	0.00537	CbGpPWpGaD
Raltegravir—CCR1—G alpha (i) signalling events—CXCR4—melanoma	0.00247	0.00515	CbGpPWpGaD
Raltegravir—CCR1—GPCR ligand binding—CCR7—melanoma	0.00247	0.00515	CbGpPWpGaD
Raltegravir—CCR1—GPCR ligand binding—GRM1—melanoma	0.00247	0.00515	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—TAS2R60—melanoma	0.00241	0.00503	CbGpPWpGaD
Raltegravir—CCR1—GPCRs, Class A Rhodopsin-like—CXCR4—melanoma	0.00229	0.00478	CbGpPWpGaD
Raltegravir—CCR1—Class A/1 (Rhodopsin-like receptors)—F2R—melanoma	0.00228	0.00477	CbGpPWpGaD
Raltegravir—CCR1—Peptide ligand-binding receptors—EDN1—melanoma	0.00224	0.00468	CbGpPWpGaD
Raltegravir—UGT1A1—Biological oxidations—UGT2B10—melanoma	0.00223	0.00466	CbGpPWpGaD
Raltegravir—CCR1—Class A/1 (Rhodopsin-like receptors)—EDNRB—melanoma	0.00221	0.00462	CbGpPWpGaD
Raltegravir—CCR1—GPCR ligand binding—CXCR2—melanoma	0.00204	0.00427	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—PLCB4—melanoma	0.00201	0.0042	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—CXCL1—melanoma	0.00201	0.0042	CbGpPWpGaD
Raltegravir—UGT1A1—Constitutive Androstane Receptor Pathway—ABCB1—melanoma	0.00198	0.00413	CbGpPWpGaD
Raltegravir—CCR1—GPCR ligand binding—WNT5A—melanoma	0.00198	0.00413	CbGpPWpGaD
Raltegravir—CCR1—Class A/1 (Rhodopsin-like receptors)—CXCR4—melanoma	0.00196	0.0041	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—CXCL1—melanoma	0.00183	0.00381	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—PLCB4—melanoma	0.00183	0.00381	CbGpPWpGaD
Raltegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—CYP1B1—melanoma	0.0018	0.00376	CbGpPWpGaD
Raltegravir—UGT1A1—NRF2 pathway—EPHA2—melanoma	0.00179	0.00374	CbGpPWpGaD
Raltegravir—CCR1—GPCR ligand binding—F2R—melanoma	0.00174	0.00363	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—F2RL1—melanoma	0.00171	0.00357	CbGpPWpGaD
Raltegravir—UGT1A1—NRF2 pathway—SLC6A11—melanoma	0.00169	0.00352	CbGpPWpGaD
Raltegravir—CCR1—GPCR ligand binding—EDNRB—melanoma	0.00168	0.00352	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—MYO7A—melanoma	0.00167	0.0035	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—DRAP1—melanoma	0.00167	0.0035	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—GRM3—melanoma	0.00161	0.00336	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—F2RL1—melanoma	0.00155	0.00324	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—KISS1—melanoma	0.00152	0.00318	CbGpPWpGaD
Raltegravir—CCR1—Class A/1 (Rhodopsin-like receptors)—EDN1—melanoma	0.0015	0.00314	CbGpPWpGaD
Raltegravir—CCR1—GPCR ligand binding—CXCR4—melanoma	0.00149	0.00312	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—CXCR1—melanoma	0.00148	0.00308	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—GRM3—melanoma	0.00146	0.00305	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—MC1R—melanoma	0.00145	0.00304	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—TAS2R60—melanoma	0.00142	0.00297	CbGpPWpGaD
Raltegravir—UGT1A1—Metapathway biotransformation—AKR1B10—melanoma	0.00142	0.00296	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—GRM1—melanoma	0.00139	0.00291	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—CCR7—melanoma	0.00139	0.00291	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—KISS1—melanoma	0.00138	0.00289	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—CXCR1—melanoma	0.00134	0.0028	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—MC1R—melanoma	0.00132	0.00276	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—RHOB—melanoma	0.00127	0.00265	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—GRM1—melanoma	0.00127	0.00264	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—CCR7—melanoma	0.00127	0.00264	CbGpPWpGaD
Raltegravir—CCR1—Peptide ligand-binding receptors—CXCL8—melanoma	0.00121	0.00253	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—CXCR2—melanoma	0.00115	0.00241	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—RHOB—melanoma	0.00115	0.00241	CbGpPWpGaD
Raltegravir—CCR1—GPCR ligand binding—EDN1—melanoma	0.00115	0.00239	CbGpPWpGaD
Raltegravir—Hallucination—Carmustine—melanoma	0.00114	0.00219	CcSEcCtD
Raltegravir—Hypoaesthesia—Carmustine—melanoma	0.00114	0.00219	CcSEcCtD
Raltegravir—Hot flush—Docetaxel—melanoma	0.00114	0.00219	CcSEcCtD
Raltegravir—Hypersensitivity—Vemurafenib—melanoma	0.00114	0.00218	CcSEcCtD
Raltegravir—CCR1—GPCR downstream signaling—RAC2—melanoma	0.00114	0.00237	CbGpPWpGaD
Raltegravir—Oedema peripheral—Carmustine—melanoma	0.00113	0.00217	CcSEcCtD
Raltegravir—Menopausal symptoms—Docetaxel—melanoma	0.00113	0.00217	CcSEcCtD
Raltegravir—Connective tissue disorder—Carmustine—melanoma	0.00113	0.00217	CcSEcCtD
Raltegravir—Renal impairment—Docetaxel—melanoma	0.00112	0.00215	CcSEcCtD
Raltegravir—Hepatitis—Temozolomide—melanoma	0.00111	0.00213	CcSEcCtD
Raltegravir—Asthenia—Vemurafenib—melanoma	0.00111	0.00213	CcSEcCtD
Raltegravir—Visual impairment—Carmustine—melanoma	0.00111	0.00212	CcSEcCtD
Raltegravir—Hypoaesthesia—Temozolomide—melanoma	0.00111	0.00212	CcSEcCtD
Raltegravir—Hallucination—Temozolomide—melanoma	0.00111	0.00212	CcSEcCtD
Raltegravir—Chills—Dactinomycin—melanoma	0.0011	0.00211	CcSEcCtD
Raltegravir—Urinary tract disorder—Temozolomide—melanoma	0.0011	0.0021	CcSEcCtD
Raltegravir—Oedema peripheral—Temozolomide—melanoma	0.00109	0.0021	CcSEcCtD
Raltegravir—Pruritus—Vemurafenib—melanoma	0.00109	0.0021	CcSEcCtD
Raltegravir—Connective tissue disorder—Temozolomide—melanoma	0.00109	0.00209	CcSEcCtD
Raltegravir—Lethargy—Docetaxel—melanoma	0.00109	0.00209	CcSEcCtD
Raltegravir—Urethral disorder—Temozolomide—melanoma	0.00109	0.00209	CcSEcCtD
Raltegravir—Alopecia—Dactinomycin—melanoma	0.00109	0.00208	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—PLCB4—melanoma	0.00108	0.00225	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—CXCL1—melanoma	0.00108	0.00225	CbGpPWpGaD
Raltegravir—Eye disorder—Carmustine—melanoma	0.00107	0.00206	CcSEcCtD
Raltegravir—Visual impairment—Temozolomide—melanoma	0.00107	0.00205	CcSEcCtD
Raltegravir—Erythema—Dactinomycin—melanoma	0.00107	0.00205	CcSEcCtD
Raltegravir—Pain in extremity—Docetaxel—melanoma	0.00107	0.00205	CcSEcCtD
Raltegravir—Ill-defined disorder—Bleomycin—melanoma	0.00106	0.00204	CcSEcCtD
Raltegravir—Anaemia—Bleomycin—melanoma	0.00106	0.00203	CcSEcCtD
Raltegravir—Diarrhoea—Vemurafenib—melanoma	0.00106	0.00203	CcSEcCtD
Raltegravir—Migraine—Docetaxel—melanoma	0.00105	0.00202	CcSEcCtD
Raltegravir—Erythema multiforme—Temozolomide—melanoma	0.00105	0.00201	CcSEcCtD
Raltegravir—CCR1—Signaling by GPCR—CXCR2—melanoma	0.00105	0.00219	CbGpPWpGaD
Raltegravir—Eye disorder—Temozolomide—melanoma	0.00104	0.00199	CcSEcCtD
Raltegravir—Tinnitus—Temozolomide—melanoma	0.00104	0.00199	CcSEcCtD
Raltegravir—Malaise—Bleomycin—melanoma	0.00103	0.00198	CcSEcCtD
Raltegravir—CCR1—Signaling by GPCR—RAC2—melanoma	0.00103	0.00216	CbGpPWpGaD
Raltegravir—Cardiac disorder—Temozolomide—melanoma	0.00103	0.00198	CcSEcCtD
Raltegravir—CCR1—G alpha (i) signalling events—CXCL8—melanoma	0.00102	0.00214	CbGpPWpGaD
Raltegravir—Dizziness—Vemurafenib—melanoma	0.00102	0.00196	CcSEcCtD
Raltegravir—Alopecia—Carmustine—melanoma	0.00102	0.00195	CcSEcCtD
Raltegravir—CCR1—Signaling by GPCR—WNT5A—melanoma	0.00102	0.00212	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—CUL3—melanoma	0.00101	0.00212	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—TRRAP—melanoma	0.00101	0.00212	CbGpPWpGaD
Raltegravir—Angiopathy—Temozolomide—melanoma	0.00101	0.00193	CcSEcCtD
Raltegravir—Mental disorder—Carmustine—melanoma	0.00101	0.00193	CcSEcCtD
Raltegravir—Immune system disorder—Temozolomide—melanoma	0.001	0.00192	CcSEcCtD
Raltegravir—Mediastinal disorder—Temozolomide—melanoma	0.001	0.00192	CcSEcCtD
Raltegravir—Erythema—Carmustine—melanoma	0.001	0.00192	CcSEcCtD
Raltegravir—Malnutrition—Carmustine—melanoma	0.001	0.00192	CcSEcCtD
Raltegravir—Cough—Bleomycin—melanoma	0.001	0.00192	CcSEcCtD
Raltegravir—Chills—Temozolomide—melanoma	0.000997	0.00191	CcSEcCtD
Raltegravir—Ill-defined disorder—Dactinomycin—melanoma	0.000992	0.0019	CcSEcCtD
Raltegravir—Anaemia—Dactinomycin—melanoma	0.000988	0.0019	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—AKR1B10—melanoma	0.000986	0.00206	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—F2R—melanoma	0.000982	0.00205	CbGpPWpGaD
Raltegravir—Vomiting—Vemurafenib—melanoma	0.000982	0.00188	CcSEcCtD
Raltegravir—Alopecia—Temozolomide—melanoma	0.000981	0.00188	CcSEcCtD
Raltegravir—Dry skin—Docetaxel—melanoma	0.000979	0.00188	CcSEcCtD
Raltegravir—Myalgia—Bleomycin—melanoma	0.000976	0.00187	CcSEcCtD
Raltegravir—Chest pain—Bleomycin—melanoma	0.000976	0.00187	CcSEcCtD
Raltegravir—Abdominal pain upper—Docetaxel—melanoma	0.000975	0.00187	CcSEcCtD
Raltegravir—Rash—Vemurafenib—melanoma	0.000974	0.00187	CcSEcCtD
Raltegravir—Mental disorder—Temozolomide—melanoma	0.000973	0.00187	CcSEcCtD
Raltegravir—Dermatitis—Vemurafenib—melanoma	0.000973	0.00187	CcSEcCtD
Raltegravir—Back pain—Carmustine—melanoma	0.000968	0.00186	CcSEcCtD
Raltegravir—Headache—Vemurafenib—melanoma	0.000967	0.00186	CcSEcCtD
Raltegravir—Malnutrition—Temozolomide—melanoma	0.000967	0.00185	CcSEcCtD
Raltegravir—Erythema—Temozolomide—melanoma	0.000967	0.00185	CcSEcCtD
Raltegravir—Breast disorder—Docetaxel—melanoma	0.000965	0.00185	CcSEcCtD
Raltegravir—Discomfort—Bleomycin—melanoma	0.000964	0.00185	CcSEcCtD
Raltegravir—Malaise—Dactinomycin—melanoma	0.000964	0.00185	CcSEcCtD
Raltegravir—Aspartate aminotransferase increased—Docetaxel—melanoma	0.000961	0.00184	CcSEcCtD
Raltegravir—Nasopharyngitis—Docetaxel—melanoma	0.000955	0.00183	CcSEcCtD
Raltegravir—CCR1—GPCR downstream signaling—EDNRB—melanoma	0.000951	0.00199	CbGpPWpGaD
Raltegravir—Dysgeusia—Temozolomide—melanoma	0.000947	0.00182	CcSEcCtD
Raltegravir—Confusional state—Bleomycin—melanoma	0.000943	0.00181	CcSEcCtD
Raltegravir—Alanine aminotransferase increased—Docetaxel—melanoma	0.000942	0.00181	CcSEcCtD
Raltegravir—Tremor—Carmustine—melanoma	0.000937	0.0018	CcSEcCtD
Raltegravir—Back pain—Temozolomide—melanoma	0.000935	0.00179	CcSEcCtD
Raltegravir—Infection—Bleomycin—melanoma	0.000929	0.00178	CcSEcCtD
Raltegravir—Anaemia—Carmustine—melanoma	0.000925	0.00177	CcSEcCtD
Raltegravir—Agitation—Carmustine—melanoma	0.000919	0.00176	CcSEcCtD
Raltegravir—Nausea—Vemurafenib—melanoma	0.000917	0.00176	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—F2RL1—melanoma	0.000917	0.00192	CbGpPWpGaD
Raltegravir—Thrombocytopenia—Bleomycin—melanoma	0.000916	0.00176	CcSEcCtD
Raltegravir—Myalgia—Dactinomycin—melanoma	0.00091	0.00175	CcSEcCtD
Raltegravir—Tremor—Temozolomide—melanoma	0.000906	0.00174	CcSEcCtD
Raltegravir—Discomfort—Dactinomycin—melanoma	0.000899	0.00172	CcSEcCtD
Raltegravir—CCR1—GPCR downstream signaling—GAB2—melanoma	0.000898	0.00188	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—GNA11—melanoma	0.000898	0.00188	CbGpPWpGaD
Raltegravir—Ill-defined disorder—Temozolomide—melanoma	0.000897	0.00172	CcSEcCtD
Raltegravir—Anaemia—Temozolomide—melanoma	0.000894	0.00171	CcSEcCtD
Raltegravir—CCR1—Signaling by GPCR—F2R—melanoma	0.000892	0.00186	CbGpPWpGaD
Raltegravir—Agitation—Temozolomide—melanoma	0.000889	0.0017	CcSEcCtD
Raltegravir—Malaise—Temozolomide—melanoma	0.000872	0.00167	CcSEcCtD
Raltegravir—Vertigo—Temozolomide—melanoma	0.000869	0.00167	CcSEcCtD
Raltegravir—Infection—Dactinomycin—melanoma	0.000867	0.00166	CcSEcCtD
Raltegravir—Hypertension—Carmustine—melanoma	0.000864	0.00166	CcSEcCtD
Raltegravir—CCR1—Signaling by GPCR—EDNRB—melanoma	0.000864	0.0018	CbGpPWpGaD
Raltegravir—Neutropenia—Docetaxel—melanoma	0.000863	0.00166	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—GRM3—melanoma	0.000862	0.0018	CbGpPWpGaD
Raltegravir—Palpitations—Temozolomide—melanoma	0.000854	0.00164	CcSEcCtD
Raltegravir—Thrombocytopenia—Dactinomycin—melanoma	0.000854	0.00164	CcSEcCtD
Raltegravir—Musculoskeletal discomfort—Bleomycin—melanoma	0.000852	0.00163	CcSEcCtD
Raltegravir—Myalgia—Carmustine—melanoma	0.000852	0.00163	CcSEcCtD
Raltegravir—Chest pain—Carmustine—melanoma	0.000852	0.00163	CcSEcCtD
Raltegravir—Anxiety—Carmustine—melanoma	0.000849	0.00163	CcSEcCtD
Raltegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—IFNG—melanoma	0.000845	0.00177	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—CXCR4—melanoma	0.000844	0.00176	CbGpPWpGaD
Raltegravir—Cough—Temozolomide—melanoma	0.000844	0.00162	CcSEcCtD
Raltegravir—Paraesthesia—Bleomycin—melanoma	0.00084	0.00161	CcSEcCtD
Raltegravir—Weight increased—Docetaxel—melanoma	0.00084	0.00161	CcSEcCtD
Raltegravir—Weight decreased—Docetaxel—melanoma	0.000835	0.0016	CcSEcCtD
Raltegravir—CCR1—GPCR downstream signaling—GNAQ—melanoma	0.000835	0.00174	CbGpPWpGaD
Raltegravir—Hypertension—Temozolomide—melanoma	0.000835	0.0016	CcSEcCtD
Raltegravir—Confusional state—Carmustine—melanoma	0.000823	0.00158	CcSEcCtD
Raltegravir—Myalgia—Temozolomide—melanoma	0.000823	0.00158	CcSEcCtD
Raltegravir—Arthralgia—Temozolomide—melanoma	0.000823	0.00158	CcSEcCtD
Raltegravir—Infestation—Docetaxel—melanoma	0.000823	0.00158	CcSEcCtD
Raltegravir—Infestation NOS—Docetaxel—melanoma	0.000823	0.00158	CcSEcCtD
Raltegravir—Anxiety—Temozolomide—melanoma	0.00082	0.00157	CcSEcCtD
Raltegravir—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—melanoma	0.000817	0.00157	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—KISS1—melanoma	0.000817	0.00171	CbGpPWpGaD
Raltegravir—Stevens-Johnson syndrome—Docetaxel—melanoma	0.000816	0.00156	CcSEcCtD
Raltegravir—CCR1—Signaling by GPCR—GAB2—melanoma	0.000815	0.0017	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—GNA11—melanoma	0.000815	0.0017	CbGpPWpGaD
Raltegravir—Discomfort—Temozolomide—melanoma	0.000813	0.00156	CcSEcCtD
Raltegravir—Decreased appetite—Bleomycin—melanoma	0.000813	0.00156	CcSEcCtD
Raltegravir—CCR1—Class A/1 (Rhodopsin-like receptors)—CXCL8—melanoma	0.000813	0.0017	CbGpPWpGaD
Raltegravir—Infection—Carmustine—melanoma	0.000811	0.00156	CcSEcCtD
Raltegravir—Acute coronary syndrome—Docetaxel—melanoma	0.000811	0.00156	CcSEcCtD
Raltegravir—Renal failure—Docetaxel—melanoma	0.000809	0.00155	CcSEcCtD
Raltegravir—Myocardial infarction—Docetaxel—melanoma	0.000807	0.00155	CcSEcCtD
Raltegravir—Neuropathy peripheral—Docetaxel—melanoma	0.000807	0.00155	CcSEcCtD
Raltegravir—Dry mouth—Temozolomide—melanoma	0.000805	0.00154	CcSEcCtD
Raltegravir—Pain—Bleomycin—melanoma	0.0008	0.00153	CcSEcCtD
Raltegravir—Thrombocytopenia—Carmustine—melanoma	0.0008	0.00153	CcSEcCtD
Raltegravir—Confusional state—Temozolomide—melanoma	0.000796	0.00153	CcSEcCtD
Raltegravir—Musculoskeletal discomfort—Dactinomycin—melanoma	0.000795	0.00152	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—CXCR1—melanoma	0.000792	0.00165	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—SKI—melanoma	0.000792	0.00165	CbGpPWpGaD
Raltegravir—Infection—Temozolomide—melanoma	0.000784	0.0015	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—MC1R—melanoma	0.00078	0.00163	CbGpPWpGaD
Raltegravir—Hepatobiliary disease—Docetaxel—melanoma	0.000778	0.00149	CcSEcCtD
Raltegravir—Epistaxis—Docetaxel—melanoma	0.000776	0.00149	CcSEcCtD
Raltegravir—Nervous system disorder—Temozolomide—melanoma	0.000774	0.00148	CcSEcCtD
Raltegravir—Thrombocytopenia—Temozolomide—melanoma	0.000773	0.00148	CcSEcCtD
Raltegravir—Feeling abnormal—Bleomycin—melanoma	0.000771	0.00148	CcSEcCtD
Raltegravir—UGT1A1—NRF2 pathway—SLC5A5—melanoma	0.000771	0.00161	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—AKT3—melanoma	0.00077	0.00161	CbGpPWpGaD
Raltegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—CDKN1B—melanoma	0.000767	0.0016	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—CXCR4—melanoma	0.000767	0.0016	CbGpPWpGaD
Raltegravir—Skin disorder—Temozolomide—melanoma	0.000766	0.00147	CcSEcCtD
Raltegravir—Hyperhidrosis—Temozolomide—melanoma	0.000763	0.00146	CcSEcCtD
Raltegravir—Decreased appetite—Dactinomycin—melanoma	0.000758	0.00145	CcSEcCtD
Raltegravir—CCR1—Signaling by GPCR—GNAQ—melanoma	0.000758	0.00158	CbGpPWpGaD
Raltegravir—Fatigue—Dactinomycin—melanoma	0.000752	0.00144	CcSEcCtD
Raltegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—IL2—melanoma	0.000751	0.00157	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—CCR7—melanoma	0.000748	0.00156	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—GRM1—melanoma	0.000748	0.00156	CbGpPWpGaD
Raltegravir—Pain—Dactinomycin—melanoma	0.000746	0.00143	CcSEcCtD
Raltegravir—Musculoskeletal discomfort—Carmustine—melanoma	0.000744	0.00143	CcSEcCtD
Raltegravir—UGT1A1—Biological oxidations—CYP17A1—melanoma	0.000744	0.00155	CbGpPWpGaD
Raltegravir—Urticaria—Bleomycin—melanoma	0.000743	0.00143	CcSEcCtD
Raltegravir—Body temperature increased—Bleomycin—melanoma	0.00074	0.00142	CcSEcCtD
Raltegravir—Hepatitis—Docetaxel—melanoma	0.000739	0.00142	CcSEcCtD
Raltegravir—Insomnia—Carmustine—melanoma	0.000739	0.00142	CcSEcCtD
Raltegravir—Hypoaesthesia—Docetaxel—melanoma	0.000735	0.00141	CcSEcCtD
Raltegravir—UGT1A1—Metapathway biotransformation—CYP17A1—melanoma	0.000733	0.00153	CbGpPWpGaD
Raltegravir—Paraesthesia—Carmustine—melanoma	0.000733	0.00141	CcSEcCtD
Raltegravir—Urinary tract disorder—Docetaxel—melanoma	0.000729	0.0014	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—SUFU—melanoma	0.000729	0.00152	CbGpPWpGaD
Raltegravir—Oedema peripheral—Docetaxel—melanoma	0.000728	0.0014	CcSEcCtD
Raltegravir—Somnolence—Carmustine—melanoma	0.000726	0.00139	CcSEcCtD
Raltegravir—Connective tissue disorder—Docetaxel—melanoma	0.000726	0.00139	CcSEcCtD
Raltegravir—Urethral disorder—Docetaxel—melanoma	0.000724	0.00139	CcSEcCtD
Raltegravir—Feeling abnormal—Dactinomycin—melanoma	0.000719	0.00138	CcSEcCtD
Raltegravir—Musculoskeletal discomfort—Temozolomide—melanoma	0.000719	0.00138	CcSEcCtD
Raltegravir—Insomnia—Temozolomide—melanoma	0.000714	0.00137	CcSEcCtD
Raltegravir—Gastrointestinal pain—Dactinomycin—melanoma	0.000713	0.00137	CcSEcCtD
Raltegravir—Visual impairment—Docetaxel—melanoma	0.000712	0.00137	CcSEcCtD
Raltegravir—Decreased appetite—Carmustine—melanoma	0.00071	0.00136	CcSEcCtD
Raltegravir—Paraesthesia—Temozolomide—melanoma	0.000709	0.00136	CcSEcCtD
Raltegravir—Gastrointestinal disorder—Carmustine—melanoma	0.000705	0.00135	CcSEcCtD
Raltegravir—Somnolence—Temozolomide—melanoma	0.000702	0.00135	CcSEcCtD
Raltegravir—CCR1—Signaling by GPCR—AKT3—melanoma	0.0007	0.00146	CbGpPWpGaD
Raltegravir—Erythema multiforme—Docetaxel—melanoma	0.000698	0.00134	CcSEcCtD
Raltegravir—Pain—Carmustine—melanoma	0.000698	0.00134	CcSEcCtD
Raltegravir—Constipation—Carmustine—melanoma	0.000698	0.00134	CcSEcCtD
Raltegravir—Dyspepsia—Temozolomide—melanoma	0.000695	0.00133	CcSEcCtD
Raltegravir—Eye disorder—Docetaxel—melanoma	0.00069	0.00132	CcSEcCtD
Raltegravir—Body temperature increased—Dactinomycin—melanoma	0.00069	0.00132	CcSEcCtD
Raltegravir—Abdominal pain—Dactinomycin—melanoma	0.00069	0.00132	CcSEcCtD
Raltegravir—Hypersensitivity—Bleomycin—melanoma	0.000689	0.00132	CcSEcCtD
Raltegravir—Decreased appetite—Temozolomide—melanoma	0.000686	0.00132	CcSEcCtD
Raltegravir—Cardiac disorder—Docetaxel—melanoma	0.000686	0.00131	CcSEcCtD
Raltegravir—Gastrointestinal disorder—Temozolomide—melanoma	0.000681	0.00131	CcSEcCtD
Raltegravir—Fatigue—Temozolomide—melanoma	0.00068	0.00131	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—BCL2L11—melanoma	0.00068	0.00142	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—RHOB—melanoma	0.00068	0.00142	CbGpPWpGaD
Raltegravir—Constipation—Temozolomide—melanoma	0.000675	0.00129	CcSEcCtD
Raltegravir—Pain—Temozolomide—melanoma	0.000675	0.00129	CcSEcCtD
Raltegravir—Feeling abnormal—Carmustine—melanoma	0.000673	0.00129	CcSEcCtD
Raltegravir—Asthenia—Bleomycin—melanoma	0.000671	0.00129	CcSEcCtD
Raltegravir—Angiopathy—Docetaxel—melanoma	0.00067	0.00129	CcSEcCtD
Raltegravir—Gastrointestinal pain—Carmustine—melanoma	0.000668	0.00128	CcSEcCtD
Raltegravir—Immune system disorder—Docetaxel—melanoma	0.000667	0.00128	CcSEcCtD
Raltegravir—Mediastinal disorder—Docetaxel—melanoma	0.000666	0.00128	CcSEcCtD
Raltegravir—Chills—Docetaxel—melanoma	0.000663	0.00127	CcSEcCtD
Raltegravir—Pruritus—Bleomycin—melanoma	0.000662	0.00127	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—HDAC6—melanoma	0.000653	0.00137	CbGpPWpGaD
Raltegravir—Alopecia—Docetaxel—melanoma	0.000653	0.00125	CcSEcCtD
Raltegravir—Feeling abnormal—Temozolomide—melanoma	0.00065	0.00125	CcSEcCtD
Raltegravir—CCR1—GPCR downstream signaling—EDN1—melanoma	0.000647	0.00135	CbGpPWpGaD
Raltegravir—Mental disorder—Docetaxel—melanoma	0.000647	0.00124	CcSEcCtD
Raltegravir—Abdominal pain—Carmustine—melanoma	0.000646	0.00124	CcSEcCtD
Raltegravir—Body temperature increased—Carmustine—melanoma	0.000646	0.00124	CcSEcCtD
Raltegravir—Gastrointestinal pain—Temozolomide—melanoma	0.000645	0.00124	CcSEcCtD
Raltegravir—Malnutrition—Docetaxel—melanoma	0.000643	0.00123	CcSEcCtD
Raltegravir—Erythema—Docetaxel—melanoma	0.000643	0.00123	CcSEcCtD
Raltegravir—Hypersensitivity—Dactinomycin—melanoma	0.000643	0.00123	CcSEcCtD
Raltegravir—CCR1—GPCR downstream signaling—CSF2—melanoma	0.000633	0.00132	CbGpPWpGaD
Raltegravir—Dysgeusia—Docetaxel—melanoma	0.00063	0.00121	CcSEcCtD
Raltegravir—Urticaria—Temozolomide—melanoma	0.000627	0.0012	CcSEcCtD
Raltegravir—Asthenia—Dactinomycin—melanoma	0.000626	0.0012	CcSEcCtD
Raltegravir—UGT1A1—Biological oxidations—CYP1B1—melanoma	0.000626	0.00131	CbGpPWpGaD
Raltegravir—Body temperature increased—Temozolomide—melanoma	0.000624	0.0012	CcSEcCtD
Raltegravir—Abdominal pain—Temozolomide—melanoma	0.000624	0.0012	CcSEcCtD
Raltegravir—Back pain—Docetaxel—melanoma	0.000622	0.00119	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—CXCR2—melanoma	0.000619	0.00129	CbGpPWpGaD
Raltegravir—CCR1—GPCR ligand binding—CXCL8—melanoma	0.000619	0.00129	CbGpPWpGaD
Raltegravir—UGT1A1—Metapathway biotransformation—CYP1B1—melanoma	0.000617	0.00129	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—RAC2—melanoma	0.000609	0.00127	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—PRKCA—melanoma	0.000607	0.00127	CbGpPWpGaD
Raltegravir—Hypersensitivity—Carmustine—melanoma	0.000602	0.00115	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—WNT5A—melanoma	0.0006	0.00125	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—VEGFC—melanoma	0.0006	0.00125	CbGpPWpGaD
Raltegravir—Diarrhoea—Dactinomycin—melanoma	0.000597	0.00115	CcSEcCtD
Raltegravir—Vomiting—Bleomycin—melanoma	0.000595	0.00114	CcSEcCtD
Raltegravir—Anaemia—Docetaxel—melanoma	0.000594	0.00114	CcSEcCtD
Raltegravir—Rash—Bleomycin—melanoma	0.00059	0.00113	CcSEcCtD
Raltegravir—Dermatitis—Bleomycin—melanoma	0.000589	0.00113	CcSEcCtD
Raltegravir—CCR1—Signaling by GPCR—EDN1—melanoma	0.000588	0.00123	CbGpPWpGaD
Raltegravir—Asthenia—Carmustine—melanoma	0.000586	0.00112	CcSEcCtD
Raltegravir—Hypersensitivity—Temozolomide—melanoma	0.000581	0.00112	CcSEcCtD
Raltegravir—CCR1—Signaling by GPCR—CSF2—melanoma	0.000575	0.0012	CbGpPWpGaD
Raltegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—EGFR—melanoma	0.000574	0.0012	CbGpPWpGaD
Raltegravir—UGT1A1—NRF2 pathway—HGF—melanoma	0.00057	0.00119	CbGpPWpGaD
Raltegravir—Palpitations—Docetaxel—melanoma	0.000568	0.00109	CcSEcCtD
Raltegravir—Asthenia—Temozolomide—melanoma	0.000566	0.00109	CcSEcCtD
Raltegravir—CCR1—GPCR downstream signaling—RAC1—melanoma	0.000562	0.00117	CbGpPWpGaD
Raltegravir—Cough—Docetaxel—melanoma	0.000561	0.00108	CcSEcCtD
Raltegravir—Diarrhoea—Carmustine—melanoma	0.000559	0.00107	CcSEcCtD
Raltegravir—Pruritus—Temozolomide—melanoma	0.000558	0.00107	CcSEcCtD
Raltegravir—Nausea—Bleomycin—melanoma	0.000556	0.00107	CcSEcCtD
Raltegravir—Hypertension—Docetaxel—melanoma	0.000555	0.00106	CcSEcCtD
Raltegravir—Vomiting—Dactinomycin—melanoma	0.000555	0.00106	CcSEcCtD
Raltegravir—CCR1—Signaling by GPCR—PRKCA—melanoma	0.000551	0.00115	CbGpPWpGaD
Raltegravir—Rash—Dactinomycin—melanoma	0.00055	0.00106	CcSEcCtD
Raltegravir—Arthralgia—Docetaxel—melanoma	0.000547	0.00105	CcSEcCtD
Raltegravir—Chest pain—Docetaxel—melanoma	0.000547	0.00105	CcSEcCtD
Raltegravir—Myalgia—Docetaxel—melanoma	0.000547	0.00105	CcSEcCtD
Raltegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—TNF—melanoma	0.000547	0.00114	CbGpPWpGaD
Raltegravir—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—melanoma	0.000544	0.00104	CcSEcCtD
Raltegravir—Dizziness—Carmustine—melanoma	0.00054	0.00104	CcSEcCtD
Raltegravir—Diarrhoea—Temozolomide—melanoma	0.00054	0.00104	CcSEcCtD
Raltegravir—CCR1—Signaling by GPCR—MAP2K2—melanoma	0.000538	0.00112	CbGpPWpGaD
Raltegravir—Dry mouth—Docetaxel—melanoma	0.000535	0.00103	CcSEcCtD
Raltegravir—Confusional state—Docetaxel—melanoma	0.000529	0.00102	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—F2R—melanoma	0.000527	0.0011	CbGpPWpGaD
Raltegravir—Dizziness—Temozolomide—melanoma	0.000522	0.001	CcSEcCtD
Raltegravir—Infection—Docetaxel—melanoma	0.000521	0.001	CcSEcCtD
Raltegravir—Vomiting—Carmustine—melanoma	0.000519	0.000996	CcSEcCtD
Raltegravir—Nausea—Dactinomycin—melanoma	0.000518	0.000994	CcSEcCtD
Raltegravir—Rash—Carmustine—melanoma	0.000515	0.000988	CcSEcCtD
Raltegravir—Nervous system disorder—Docetaxel—melanoma	0.000515	0.000987	CcSEcCtD
Raltegravir—Dermatitis—Carmustine—melanoma	0.000514	0.000987	CcSEcCtD
Raltegravir—Thrombocytopenia—Docetaxel—melanoma	0.000514	0.000986	CcSEcCtD
Raltegravir—Headache—Carmustine—melanoma	0.000512	0.000981	CcSEcCtD
Raltegravir—CCR1—Signaling by GPCR—RAC1—melanoma	0.000511	0.00107	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—EDNRB—melanoma	0.00051	0.00107	CbGpPWpGaD
Raltegravir—Skin disorder—Docetaxel—melanoma	0.00051	0.000978	CcSEcCtD
Raltegravir—Vomiting—Temozolomide—melanoma	0.000502	0.000962	CcSEcCtD
Raltegravir—Rash—Temozolomide—melanoma	0.000498	0.000954	CcSEcCtD
Raltegravir—Dermatitis—Temozolomide—melanoma	0.000497	0.000954	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—PTK2B—melanoma	0.000495	0.00103	CbGpPWpGaD
Raltegravir—Headache—Temozolomide—melanoma	0.000494	0.000948	CcSEcCtD
Raltegravir—Nausea—Carmustine—melanoma	0.000485	0.00093	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—GNA11—melanoma	0.000482	0.00101	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—GAB2—melanoma	0.000482	0.00101	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—FLT1—melanoma	0.00048	0.001	CbGpPWpGaD
Raltegravir—Musculoskeletal discomfort—Docetaxel—melanoma	0.000478	0.000917	CcSEcCtD
Raltegravir—CCR1—GPCR downstream signaling—PIK3CG—melanoma	0.000475	0.000993	CbGpPWpGaD
Raltegravir—Insomnia—Docetaxel—melanoma	0.000475	0.00091	CcSEcCtD
Raltegravir—Paraesthesia—Docetaxel—melanoma	0.000471	0.000904	CcSEcCtD
Raltegravir—Nausea—Temozolomide—melanoma	0.000469	0.000899	CcSEcCtD
Raltegravir—Somnolence—Docetaxel—melanoma	0.000467	0.000895	CcSEcCtD
Raltegravir—Dyspepsia—Docetaxel—melanoma	0.000462	0.000886	CcSEcCtD
Raltegravir—Decreased appetite—Docetaxel—melanoma	0.000456	0.000875	CcSEcCtD
Raltegravir—Gastrointestinal disorder—Docetaxel—melanoma	0.000453	0.000869	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—HDAC2—melanoma	0.000453	0.000946	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—CXCR4—melanoma	0.000453	0.000946	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—FOXO4—melanoma	0.000453	0.000946	CbGpPWpGaD
Raltegravir—Fatigue—Docetaxel—melanoma	0.000452	0.000868	CcSEcCtD
Raltegravir—Pain—Docetaxel—melanoma	0.000449	0.000861	CcSEcCtD
Raltegravir—Constipation—Docetaxel—melanoma	0.000449	0.000861	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—GNAQ—melanoma	0.000448	0.000936	CbGpPWpGaD
Raltegravir—Feeling abnormal—Docetaxel—melanoma	0.000432	0.00083	CcSEcCtD
Raltegravir—CCR1—Signaling by GPCR—PIK3CG—melanoma	0.000431	0.000901	CbGpPWpGaD
Raltegravir—Gastrointestinal pain—Docetaxel—melanoma	0.000429	0.000823	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—SYK—melanoma	0.000421	0.00088	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—PIK3CD—melanoma	0.000418	0.000873	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—ACER3—melanoma	0.000417	0.000872	CbGpPWpGaD
Raltegravir—Abdominal pain—Docetaxel—melanoma	0.000415	0.000796	CcSEcCtD
Raltegravir—Body temperature increased—Docetaxel—melanoma	0.000415	0.000796	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—AKT3—melanoma	0.000413	0.000863	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—ITGAV—melanoma	0.000413	0.000863	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—NGFR—melanoma	0.000413	0.000863	CbGpPWpGaD
Raltegravir—Hypersensitivity—Docetaxel—melanoma	0.000387	0.000742	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—SOCS1—melanoma	0.000383	0.000799	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—MAP2K1—melanoma	0.000382	0.000798	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—S100B—melanoma	0.000382	0.000797	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—UGT2B10—melanoma	0.000382	0.000797	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—PIK3CD—melanoma	0.000379	0.000792	CbGpPWpGaD
Raltegravir—Asthenia—Docetaxel—melanoma	0.000377	0.000722	CcSEcCtD
Raltegravir—Pruritus—Docetaxel—melanoma	0.000371	0.000712	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—ERBB4—melanoma	0.000365	0.000763	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—PIK3CB—melanoma	0.000364	0.000761	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—CDKN2B—melanoma	0.000362	0.000756	CbGpPWpGaD
Raltegravir—Diarrhoea—Docetaxel—melanoma	0.000359	0.000689	CcSEcCtD
Raltegravir—UGT1A1—Metabolism—HS3ST5—melanoma	0.000355	0.000741	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—CD86—melanoma	0.00035	0.000731	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—CXCL8—melanoma	0.00035	0.000731	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—EDN1—melanoma	0.000347	0.000725	CbGpPWpGaD
Raltegravir—Dizziness—Docetaxel—melanoma	0.000347	0.000666	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—FGF1—melanoma	0.000339	0.000709	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—CSF2—melanoma	0.000339	0.000709	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—IL2—melanoma	0.000334	0.000698	CbGpPWpGaD
Raltegravir—Vomiting—Docetaxel—melanoma	0.000334	0.00064	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—E2F1—melanoma	0.000332	0.000694	CbGpPWpGaD
Raltegravir—Rash—Docetaxel—melanoma	0.000331	0.000635	CcSEcCtD
Raltegravir—CCR1—Signaling by GPCR—PIK3CB—melanoma	0.000331	0.000691	CbGpPWpGaD
Raltegravir—Dermatitis—Docetaxel—melanoma	0.000331	0.000634	CcSEcCtD
Raltegravir—Headache—Docetaxel—melanoma	0.000329	0.000631	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—PDGFRA—melanoma	0.000329	0.000687	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—ITGB3—melanoma	0.000325	0.00068	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—PRKCA—melanoma	0.000325	0.00068	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—SPP1—melanoma	0.000319	0.000667	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—MAP2K2—melanoma	0.000318	0.000665	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—CXCL8—melanoma	0.000318	0.000664	CbGpPWpGaD
Raltegravir—Nausea—Docetaxel—melanoma	0.000312	0.000598	CcSEcCtD
Raltegravir—CCR1—Signaling by GPCR—IL2—melanoma	0.000304	0.000634	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—TERT—melanoma	0.000303	0.000632	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—RAC1—melanoma	0.000302	0.00063	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—HIF1A—melanoma	0.000289	0.000604	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—KDR—melanoma	0.000277	0.000578	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—PLCB4—melanoma	0.000269	0.000562	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—FN1—melanoma	0.000266	0.000556	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—NOTCH1—melanoma	0.000261	0.000544	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—CD80—melanoma	0.000255	0.000533	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—APC—melanoma	0.000255	0.000532	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—PIK3CG—melanoma	0.000255	0.000532	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—KIT—melanoma	0.000255	0.000532	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—NRAS—melanoma	0.000255	0.000532	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—SLC6A11—melanoma	0.000253	0.000528	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—PIP4K2A—melanoma	0.000253	0.000528	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—EGF—melanoma	0.000252	0.000526	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—MTAP—melanoma	0.000246	0.000514	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—MAPK3—melanoma	0.000244	0.00051	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—BRAF—melanoma	0.00024	0.0005	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—IGF1—melanoma	0.000233	0.000488	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—MAPK1—melanoma	0.000232	0.000485	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—EGFR—melanoma	0.000232	0.000485	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—MAP2K1—melanoma	0.000226	0.000471	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—PIK3CD—melanoma	0.000224	0.000468	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—PIK3CA—melanoma	0.000222	0.000464	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—KRAS—melanoma	0.000219	0.000458	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—LUM—melanoma	0.000219	0.000458	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—PHGDH—melanoma	0.000219	0.000458	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—HPSE—melanoma	0.000215	0.000449	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—FGF2—melanoma	0.000215	0.000448	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—CUBN—melanoma	0.000211	0.000441	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—SDHD—melanoma	0.000204	0.000426	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—CSPG4—melanoma	0.000204	0.000426	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—BSG—melanoma	0.000204	0.000426	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—PIK3CA—melanoma	0.000202	0.000421	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—MDM2—melanoma	0.000201	0.000419	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—ERBB2—melanoma	0.000198	0.000413	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—GPAM—melanoma	0.000197	0.000412	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—PIK3CB—melanoma	0.000195	0.000408	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—CXCL8—melanoma	0.000188	0.000392	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—HRAS—melanoma	0.000186	0.00039	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—CDKN1B—melanoma	0.000183	0.000383	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—AKT1—melanoma	0.000181	0.000379	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—CASP3—melanoma	0.00018	0.000375	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—IL2—melanoma	0.000179	0.000375	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—IL6—melanoma	0.000178	0.000373	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—CCND1—melanoma	0.000175	0.000365	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—CTNNB1—melanoma	0.000173	0.000362	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—MMP9—melanoma	0.00017	0.000355	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—CDKN1A—melanoma	0.000169	0.000353	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—PTEN—melanoma	0.000169	0.000353	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—NFKB1—melanoma	0.000168	0.000351	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—PLA2G6—melanoma	0.000168	0.000351	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—AKT1—melanoma	0.000165	0.000344	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—VEGFA—melanoma	0.000152	0.000318	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—STAT3—melanoma	0.000151	0.000315	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—VCAN—melanoma	0.000151	0.000315	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—NRAS—melanoma	0.000151	0.000315	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—MAPK3—melanoma	0.000144	0.000301	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—MYC—melanoma	0.00014	0.000293	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—MAPK1—melanoma	0.000137	0.000287	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—EGFR—melanoma	0.000137	0.000287	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—KRAS—melanoma	0.00013	0.000271	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—CYP17A1—melanoma	0.000127	0.000266	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—GNA11—melanoma	0.00012	0.000251	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—PIK3CA—melanoma	0.000119	0.000249	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—FASN—melanoma	0.000118	0.000246	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—SLC5A5—melanoma	0.000116	0.000242	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—TP53—melanoma	0.000115	0.000241	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—GNAQ—melanoma	0.000112	0.000233	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—CD44—melanoma	0.000112	0.000233	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—HRAS—melanoma	0.00011	0.00023	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—CYP1B1—melanoma	0.000107	0.000224	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—IL6—melanoma	0.000105	0.00022	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—AKT1—melanoma	9.73e-05	0.000203	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—ABCB1—melanoma	8.81e-05	0.000184	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—PRKCA—melanoma	8.11e-05	0.000169	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—ERCC2—melanoma	8.05e-05	0.000168	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—PIK3CG—melanoma	6.35e-05	0.000133	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—PPARG—melanoma	6.13e-05	0.000128	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—PIK3CD—melanoma	5.59e-05	0.000117	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—ALB—melanoma	5.51e-05	0.000115	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—PIK3CB—melanoma	4.87e-05	0.000102	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—PTGS2—melanoma	4.82e-05	0.000101	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—PTEN—melanoma	4.21e-05	8.79e-05	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—PIK3CA—melanoma	2.97e-05	6.2e-05	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—AKT1—melanoma	2.42e-05	5.07e-05	CbGpPWpGaD
